Jan Ter Meulen

List of Publications by Year
in descending order

47 papers	4,548 citations	147801 31 h-index	223800 46 g-index
47 all docs	47 docs citations	47 times ranked	6502 citing authors

#	Article	IF	Citations
1	Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells. PLoS ONE, 2008, 3, e3942.	2.5	676
2	Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants. PLoS Medicine, 2006, 3, e237.	8.4	594
3	Hantavirus in African Wood Mouse, Guinea. Emerging Infectious Diseases, 2006, 12, 838-840.	4.3	266
4	Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet, The, 2004, 363, 2139-2141.	13.7	252
5	Lassa Virus Z Protein Is a Matrix Protein Sufficient for the Release of Virus-Like Particles. Journal of Virology, 2003, 77, 10700-10705.	3.4	211
6	Design of an HA2-based <i>Escherichia coli</i> expressed influenza immunogen that protects mice from pathogenic challenge. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13701-13706.	7.1	201
7	<i>Mastomys natalensi</i>s and Lassa Fever, West Africa. Emerging Infectious Diseases, 2006, 12, 1971-1974.	4.3	175
8	Isolation and Characterization of Human Monoclonal Antibodies from Individuals Infected with West Nile Virus. Journal of Virology, 2006, 80, 6982-6992.	3.4	153
9	Molecular and Biological Characterization of Human Monoclonal Antibodies Binding to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome Coronavirus. Journal of Virology, 2005, 79, 1635-1644.	3.4	152
10	Novel Hantavirus Sequences in Shrew, Guinea. Emerging Infectious Diseases, 2007, 13, 520-522.	4.3	140
11	Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection. PLoS Pathogens, 2015, 11, e1005276.	4.7	138
12	Fluctuation of Abundance and Lassa Virus Prevalence in <i>Mastomys natalensis</i> in Guinea, West Africa. Vector-Borne and Zoonotic Diseases, 2007, 7, 119-128.	1.5	109
13	RT-PCR assay for detection of Lassa virus and related Old World arenaviruses targeting the L gene. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2007, 101, 1253-1264.	1.8	107
14	Characterization of Human CD4 + T-Cell Clones Recognizing Conserved and Variable Epitopes of the Lassa Virus Nucleoprotein. Journal of Virology, 2000, 74, 2186-2192.	3.4	98
15	Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma. Clinical Cancer Research, 2019, 25, 1185-1195.	7.0	97
16	Characterization of the Lassa virus matrix protein Z: electron microscopic study of virus-like particles and interaction with the nucleoprotein (NP). Virus Research, 2004, 100, 249-255.	2.2	90
17	Novel Arenavirus Sequences in Hylomyscus sp. and Mus (Nannomys) setulosus from CÃ´te d'Ivoire: Implications for Evolution of Arenaviruses in Africa. PLoS ONE, 2011, 6, e20893.	2.5	72
18	Design of Escherichia coli-Expressed Stalk Domain Immunogens of H1N1 Hemagglutinin That Protect Mice from Lethal Challenge. Journal of Virology, 2012, 86, 13434-13444.	3.4	69

#	Article	IF	Citations
19	Current Molecular Epidemiology of Lassa Virus in Nigeria. Journal of Clinical Microbiology, 2011, 49, 1157-1161.	3.9	68
20	Identification of a Novel Consensus Sequence at the Cleavage Site of the Lassa Virus Glycoprotein. Journal of Virology, 2000, 74, 11418-11421.	3.4	63
21	Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones. Virology, 2004, 321, 134-143.	2.4	60
22	Serological Evidence of Human Hantavirus Infections in Guinea, West Africa. Journal of Infectious Diseases, 2010, 201, 1031-1034.	4.0	57
23	Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial. Npj Vaccines, 2018, 3, 3.	6.0	57
24	Amino acids from both N-terminal hydrophobic regions of the Lassa virus envelope glycoprotein GP-2 are critical for pH-dependent membrane fusion and infectivity. Journal of General Virology, 2007, 88, 2320-2328.	2.9	55
25	Reproductive Characteristics of<i>Mastomys natalensis</i>and Lassa Virus Prevalence in Guinea, West Africa. Vector-Borne and Zoonotic Diseases, 2008, 8, 41-48.	1.5	53
26	Characterization of Lassa Virus Cell Entry and Neutralization with Lassa Virus Pseudoparticles. Journal of Virology, 2009, 83, 3228-3237.	3.4	51
27	First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient. Journal of Immunotherapy, 2017, 40, 302-306.	2.4	51
28	Antibody responses against wild-type yellow fever virus and the 17D vaccine strain: characterization with human monoclonal antibody fragments and neutralization escape variants. Virology, 2005, 337, 262-272.	2.4	49
29	First International Quality Assurance Study on the Rapid Detection of Viral Agents of Bioterrorism. Journal of Clinical Microbiology, 2004, 42, 1753-1755.	3.9	47
30	Sangassou Virus, the First Hantavirus Isolate from Africa, Displays Genetic and Functional Properties Distinct from Those of Other Murinae-Associated Hantaviruses. Journal of Virology, 2012, 86, 3819-3827.	3.4	44
31	The Impact of Human Conflict on the Genetics of Mastomys natalensis and Lassa Virus in West Africa. PLoS ONE, 2012, 7, e37068.	2.5	39
32	Short communication: Lassa fever in Sierra Leone: UN peacekeepers are at risk. Tropical Medicine and International Health, 2001, 6, 83-84.	2.3	32
33	Monoclonal Antibodies in Infectious Diseases: Clinical Pipeline in 2011. Infectious Disease Clinics of North America, 2011, 25, 789-802.	5.1	29
34	LV305, a dendritic cell-targeting integration-deficient ZVex TM -based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response. Molecular Therapy - Oncolytics, 2016, 3, 16010.	4.4	29
35	Monoclonal antibodies for prophylaxis and therapy of infectious diseases. Expert Opinion on Emerging Drugs, 2007, 12, 525-540.	2.4	26
36	Virological and Preclinical Characterization of a Dendritic Cell Targeting, Integration-deficient Lentiviral Vector for Cancer Immunotherapy. Journal of Immunotherapy, 2015, 38, 41-53.	2.4	24

#	Article	IF	Citations
37	A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1. OncoImmunology, 2020, 9, 1847846.	4.6	22
38	Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors. Npj Vaccines, 2020, 5, 50.	6.0	19
39	Antibodies to Lassa virus Z protein and nucleoprotein co-occur in human sera from Lassa fever endemic regions. Medical Microbiology and Immunology, 2001, 189, 225-229.	4.8	17
40	Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development. Expert Review of Vaccines, 2007, 6, 183-191.	4.4	16
41	Therapeutic efficacy of PD1/PDL1 blockade in B16 melanoma is greatly enhanced by immunization with dendritic cell-targeting lentiviral vector and protein vaccine. Vaccine, 2020, 38, 3369-3377.	3.8	11
42	In vitro and in vivo characterization of designed immunogens derived from the CD-helix of the stem of influenza hemagglutinin. Proteins: Structure, Function and Bioinformatics, 2013, 81, 1759-1775.	2.6	10
43	Intratumoral Injection of TLR4 Agonist (G100) Leads to Tumor Regression of A20 Lymphoma and Induces Abscopal Responses. Blood, 2015, 126, 820-820.	1.4	8
44	Pushing the envelope on HIV-1 neutralization. Nature Biotechnology, 2010, 28, 929-931.	17.5	5
45	The potential of targeted antibody prophylaxis in SARS outbreak control: A mathematic analysis. Travel Medicine and Infectious Disease, 2007, 5, 70-78.	3.0	2
46	Winning a Race Against Evolving Pathogens with Novel Platforms and Universal Vaccines. , 2015, , 251-287.		2
47	Intratumoral expression of IL-12 from lentiviral or RNA vectors acts synergistically with TLR4 agonist (GLA) to generate anti-tumor immunological memory. PLoS ONE, 2021, 16, e0259301.	2.5	2